Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment

On a much affirmative front, connected June 13, Johnson & Johnson announced that Halozyme-partnered Darzalex Faspro, erstwhile utilized with its crab cause Talvey, importantly improved endurance outcomes successful a late-stage proceedings for patients with aggregate myeloma. The operation reduced the hazard of decease by up to 53% compared with the modular treatment. Darzalex Faspro is simply a front-line aggregate myeloma therapy. The operation of 2 drugs, aft astir 2 years of follow-up, reduced the hazard of crab worsening oregon decease by up to 72%. Additionally, astatine 24 months, astir 89% of patients were alive, compared with 79% of those receiving modular care. The affirmative proceedings results could payment HALO by supporting continued adoption of Darzalex Faspro, which uses the company's ENHANZE technology.

Halozyme Therapeutics Inc. (NASDAQ:HALO) is simply a biopharmaceutical company. It researches, develops, and commercializes proprietary enzymes and devices. The company's products are based connected the patented recombinant quality hyaluronidase enzyme that enables transportation of injectable biologics, specified arsenic monoclonal antibodies and different therapeutic molecules. The institution was founded successful 1998 and is headquartered successful San Diego, California.

While we admit the imaginable of HALO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best AI Stocks to Watch successful July and 12 Best Dow Stocks to Invest In Right Now. 

Disclosure: None. Follow Insider Monkey connected Google News.